Pacira BioSciences, Inc. (PCRX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+477.2%

$210.11

vs $36.40 price

Levered DCF

$231.81

After debt service

Piotroski score

8 / 9

Strong

Altman Z-score

2.46

Grey zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	161.75×	-8.76×	37.08×	110.31×	63.34×	17.55×	-167.78×	-3,740.87×
P/B	1.66×	1.12×	1.79×	2.27×	3.65×	4.12×	5.3×	5.48×
P/S	1.59×	1.24×	2.31×	2.64×	4.92×	5.94×	4.47×	5.22×
EV / EBITDA	11.83×	42.36×	12.89×	17.22×	28.14×	47.15×	70.06×	58.04×
Gross margin	79.4%	75.7%	72.6%	70.1%	74.1%	72.7%	74.7%	74.3%
Operating margin	4.6%	-10.5%	13.0%	9.0%	16.6%	10.8%	2.5%	4.7%
Net margin	1.0%	-14.2%	6.2%	2.4%	7.8%	33.9%	-2.6%	-0.1%
Current ratio	4.54×	2.4×	5.24×	3.37×	1.66×	2.57×	3.79×	7.88×
Debt / equity	0.66×	0.82×	0.67×	0.99×	1.55×	0.87×	0.99×	0.91×
Interest coverage	2.28×	-4.43×	5.06×	1.69×	3.1×	1.81×	0.44×	0.73×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	1.0%	-12.8%	4.8%	2.1%	5.7%	23.5%	-3.1%	-0.1%
Return on invested capital	1.2%	-5.0%	4.0%	3.8%	3.5%	3.9%	1.4%	2.5%
Return on assets	0.6%	-6.4%	2.7%	0.9%	2.0%	11.4%	-1.3%	-0.1%
Free cash flow yield	11.8%	20.5%	8.9%	6.6%	3.0%	1.5%	3.2%	2.0%
Earnings yield	0.6%	-11.4%	2.7%	0.9%	1.6%	5.7%	-0.6%	-0.0%
Enterprise value	$1.4B	$1.2B	$2B	$2.4B	$3.2B	$3B	$2.2B	$1.9B
Net debt / EBITDA	2.41×	12.43×	2.8×	4.7×	4.77×	6.95×	8.9×	4.79×
Cash conversion cycle (days)	398	286	232	202	294	214	197	185